SCHEMBL673159

SCHEMBL673159

NS(=O)(=O)c1ccc(NC(=O)Nc2ccccc2-c2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA2 P00918 15/20 1.00
CA1 P00915 14/20 1.00
CA9 Q16790 14/20 1.00
CA12 O43570 13/20 1.00
CYP1A2 P05177 2/20 0.67
KMT2A Q03164 2/20 0.64
POLB P06746 2/20 0.64
MEN1 O00255 1/20 0.57
PSMD14 O00487 1/20 0.57
MAPT P10636 1/20 0.57
RECQL P46063 1/20 0.57
CACNA1B Q00975 1/20 0.57
APBA1 Q02410 1/20 0.57
CTDSP1 Q9GZU7 1/20 0.57
SAE1 Q9UBE0 1/20 0.57
UBA2 Q9UBT2 1/20 0.57
CA4 P22748 1/20 0.56
CA7 P43166 1/20 0.56
PTPN7 P35236 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30090655 1.00 CA2 (1.00) CA2CA1CA9CA12CYP1A2
SCHEMBL14726223 0.86 CA1 (0.76) CA2CA1CA9CA12CYP1A2
SCHEMBL29776946 0.83 CA12 (0.70) CA2CA1CA9CA12KMT2A
SCHEMBL671546 0.83 CA2 (1.00) CA2CA1CA9CA12CYP1A2
SCHEMBL3406989 0.80 CA2 (0.70) CA2CA1CA9CA12CYP1A2
SCHEMBL672763 0.80 CA12 (1.00) CA2CA1CA9CA12CYP1A2
SCHEMBL34420050 0.80 CA12 (0.64) CA2CA1CA9CA12KMT2A
SCHEMBL28499329 0.80 KMT2A (1.00) CA2CA1CA9CA12KMT2A
SCHEMBL1463249 0.78 POLB (1.00) CA2CA1CA9CA12CYP1A2
SCHEMBL23086242 0.77 CA2 (0.87) CA2CA1CA9CA12KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130190396-A1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH METASIGNAL THERAPEUTICS INC. (CA) 2013-07-25 US claimed
EP-2590938-A1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH Metasignal Therapeutics Inc. (CA) 2013-05-15 EP claimed
WO-2012021963-A1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH METASIGNAL THERAPEUTICS INC. (CA) 2012-02-23 WO claimed
CN-115414480-A Dianhydrogalactitol in combination with radiation for treatment of non-small cell lung cancer and glioblastoma multiforme 德玛医药 2022-12-02 CN disclosed
US-20190015379-A1 USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS DEL MAR PHARMACEUTICALS (BC) LTD. (CA) 2019-01-17 US disclosed
US-9962398-B2 Sulfonamide compounds for inhibition of metastatic tumor growth WELICHEM BIOTECH INC. (CA) 2018-05-08 US disclosed
US-9962398-B2 Sulfonamide compounds for inhibition of metastatic tumor growth WELICHEM BIOTECH INC. (CA) 2018-05-08 US disclosed
EP-3217970-A1 DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME Del Mar Pharmaceuticals (CA) 2017-09-20 EP disclosed
EP-2590938-B1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH WELICHEM BIOTECH INC (CA) 2017-06-07 EP disclosed
US-20170007627-A1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH WELICHEM BIOTECH INC. (CA) 2017-01-12 US disclosed
US-20170007627-A1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH WELICHEM BIOTECH INC. (CA) 2017-01-12 US disclosed
US-9463171-B2 Sulfonamide compounds for inhibition of metastatic tumor growth WELICHEM BIOTECH INC. (CA) 2016-10-11 US disclosed
US-9463171-B2 Sulfonamide compounds for inhibition of metastatic tumor growth WELICHEM BIOTECH INC. (CA) 2016-10-11 US disclosed
CN-103221388-B For the novel sulfonamide compounds suppressing metastatic tumo(u)r to grow 维理生物技术公司 2016-09-28 CN disclosed
WO-2016077264-A1 DIANHYDROGALACTITOL TOGETHER WITH RADIATION TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME DEL MAR PHARMACEUTICALS (CA) 2016-05-19 WO disclosed
US-20130190396-A1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH METASIGNAL THERAPEUTICS INC. (CA) 2013-07-25 US disclosed
US-20130190396-A1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH METASIGNAL THERAPEUTICS INC. (CA) 2013-07-25 US disclosed
EP-2590938-A1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH Metasignal Therapeutics Inc. (CA) 2013-05-15 EP disclosed
WO-2012021963-A1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH METASIGNAL THERAPEUTICS INC. (CA) 2012-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190396-A1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH HIF1AN, CBX2, HIF1A CA2 5/4885CA1 31/4885CA9 25/4885
US-20190015379-A1 USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS MGMT, DCLRE1A, DNMT1 CA2 4654/4885CA1 2097/4885CA9 3444/4885
US-20170007627-A1 NOVEL SULFONAMIDE COMPOUNDS FOR INHIBITION OF METASTATIC TUMOR GROWTH HIF1AN, CBX2, HIF1A CA2 5/4885CA1 31/4885CA9 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.